Global Pemphigus Vulgaris Market- Industry Analysis and Forecast (2020-2027)- By Treatment, Route of Administration, End-Users, and Region.

Global Pemphigus Vulgaris market was valued US$ 423.43 Mn in 2019 and is expected to reach 689.34 Mn by 2027, at a CAGR of 8.4 % during a forecast period.   Global Pemphigus Vulgaris market To know about the Research Methodology :- Request Free Sample Report

Global Pemphigus Vulgaris market Definition:

Pemphigus Vulgaris is a rare autoimmune disease that is characterised by painful blisters and erosions on the skin and mucous membranes, most commonly inside the mouth. Pemphigus Vulgaris accounts for 70% of all pemphigus cases worldwide although it is extremely rare in New Zealand ~1 case in 1Mn of the population. Pemphigus Vulgaris affects both men and women. The two main subtypes of pemphigus are pemphigus foliaceus and paraneoplastic pemphigus. The report study has analyzed the revenue impact of COVID-19 pandemic on the sales revenue of market leaders, market followers, and disrupters in the report, and the same is reflected in our analysis. Global Pemphigus Vulgaris Market Snapshot

Global Pemphigus Vulgaris market Dynamics:

The major factor which is influencing the market growth is documented for the rising bacterial and viral infection, growing occurrence of pemphigus Vulgaris, increasing cases of cancer across the globe. On the other hand, advancement in medicine and diagnostic procedures is expected to drive the market growth for the long run. Vigorous healthcare infrastructure is expected to propel the market in the coming years. As there are limited options available in the market for Pemphigus Vulgaris treatment, and various side effects of marketed non-biological drugs, boost up the research for Pemphigus Vulgaris treatment and will simultaneously help the global Pemphigus Vulgaris market to expand. However, factors like unfavourable reimbursement situation, high cost related to treatment, and lack of awareness are expected to hinder the market growth.

Global Pemphigus Vulgaris market Segment analysis:

From the treatment segment, the corticosteroids segment is expected to dominate the treatment segment amongst other types as the primary main target of treatment is to decrease blister formation, prevent infections, and promote healing of blisters and erosions. Systemic corticosteroids are the backbone of medical treatment for controlling the disease, usually in the form of moderate to high doses of oral prednisone or prednisolone, or as pulsed intravenous methylprednisolone. Since their use, many deaths from Pemphigus Vulgaris have been prevented and the mortality rate dropped from 99% to 5-15%. Corticosteroids are not a cure for the disease but improve the patient's quality of life by reducing disease activity.

Global Pemphigus Vulgaris market Regional Analysis:

Regionally, North America is expected to dominate Pemphigus Vulgaris Market, and expected to show steady growth during the forecasted period. leading growth factor is considered as the development of new drugs in the region, primarily in the United States. change in lifestyle is the main region to boost the number of patients in this region. Factors like growth in the geriatric population, huge funding in the R &D activity for such rare disease is expected to drive the market growth in this region. The mounting research and development activities in the region are projected to run the innovation of highly effective and improved drugs for the treatment of the targeted market. Developed pharmaceutical infrastructure and technology in this region will boost the market growth by 2020-2027. On the other hand, Europe is expected to show substantial market growth owing to their economic stability and growing awareness and adoption of new technology and trend. Result of this, Europe is estimated to hold the second-largest share in the market owing to the growth in adult population along with rising research and development activities aiming at Pemphigus Vulgaris disease in the region. The objective of the report is to present a comprehensive analysis of the Global Pemphigus Vulgaris Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analysed, which will give a clear futuristic view of the industry to the decision-makers.

Global Pemphigus Vulgaris market Industrial Update:

In February 2018, Roche announced that the US Food and Drug Administration (FDA) had accepted the company’s supplemental biologics license application (SBLA) and approved priority review for the use of MabThera/Rituxan (Rituximab) for the treatment of pemphigus Vulgaris (PV), a rare, life-threatening condition characterized by progressive painful blistering of the skin and mucous membranes. The report also helps in understanding Global Pemphigus Vulgaris Market dynamics, structure by analysing the market segments and project the Global Pemphigus Vulgaris Market size. Clear representation of competitive analysis of key players by Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Global Pemphigus Vulgaris Market make the report investor’s guide.

Global Pemphigus Vulgaris Market Scope: Inquire before buying

Global Pemphigus Vulgaris market, by Treatment

• Intravenous Immunoglobulin (IVIG) Therapy • Corticosteroids • Immunosuppressant’s • Biological Therapies • Others

Global Pemphigus Vulgaris market, by Route of Administration

• Subcutaneous • Intravenous • Oral

Global Pemphigus Vulgaris market, by End-Users

• Research & Academic Laboratories • Specialty Dermatology Clinics • Hospitals & Clinics • Retailers • Pharmacy • E-Commerce

Global Pemphigus Vulgaris Market, by Region

• North America • Europe • Asia Pacific • Latin America • Middle East & Africa

Global Pemphigus Vulgaris market Key Players

Teva Pharmaceutical IndustriesNovartis Pharmaceuticals,Hoffmann-La Roche,Principia Biopharma, Inc, • Argenx • Pfizer Inc., • Teligent Inc, • GlaxoSmithKline LLC, • Almirall • Argenx SE • Biogen Inc • Syntimmune • Sanofi • Janssen Global Services • Genentech Inc. • Celltrion Inc. • Amgen Inc. • Samsung Bioepis. • Fresenius Kabi USA. • Hikma Pharmaceutical PLC.
Global Pemphigus Vulgaris Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Pemphigus Vulgaris Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Pemphigus Vulgaris Market Analysis and Forecast 6.1. Pemphigus Vulgaris Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Pemphigus Vulgaris Market Analysis and Forecast, By Treatment 7.1. Introduction and Definition 7.2. Key Findings 7.3. Pemphigus Vulgaris Market Value Share Analysis, By Treatment 7.4. Pemphigus Vulgaris Market Size (US$ Bn) Forecast, By Treatment 7.5. Pemphigus Vulgaris Market Analysis, By Treatment 7.6. Pemphigus Vulgaris Market Attractiveness Analysis, By Treatment 8. Pemphigus Vulgaris Market Analysis and Forecast, By Route of Administration 8.1. Introduction and Definition 8.2. Key Findings 8.3. Pemphigus Vulgaris Market Value Share Analysis, By Route of Administration 8.4. Pemphigus Vulgaris Market Size (US$ Bn) Forecast, By Route of Administration 8.5. Pemphigus Vulgaris Market Analysis, By Route of Administration 8.6. Pemphigus Vulgaris Market Attractiveness Analysis, By Route of Administration 9. Pemphigus Vulgaris Market Analysis and Forecast, By End-Users 9.1. Introduction and Definition 9.2. Key Findings 9.3. Pemphigus Vulgaris Market Value Share Analysis, By End-Users 9.4. Pemphigus Vulgaris Market Size (US$ Bn) Forecast, By End-Users 9.5. Pemphigus Vulgaris Market Analysis, By End-Users 9.6. Pemphigus Vulgaris Market Attractiveness Analysis, By End-Users 10. Pemphigus Vulgaris Market Analysis, by Region 10.1. Pemphigus Vulgaris Market Value Share Analysis, by Region 10.2. Pemphigus Vulgaris Market Size (US$ Bn) Forecast, by Region 10.3. Pemphigus Vulgaris Market Attractiveness Analysis, by Region 11. North America Pemphigus Vulgaris Market Analysis 11.1. Key Findings 11.2. North America Pemphigus Vulgaris Market Overview 11.3. North America Pemphigus Vulgaris Market Value Share Analysis, By Treatment 11.4. North America Pemphigus Vulgaris Market Forecast, By Treatment 11.4.1. Intravenous Immunoglobulin (IVIG) Therapy 11.4.2. Corticosteroids 11.4.3. Immunosuppressant’s 11.4.4. Biological Therapies 11.4.5. Others 11.5. North America Pemphigus Vulgaris Market Value Share Analysis, By Route of Administration 11.6. North America Pemphigus Vulgaris Market Forecast, By Route of Administration 11.6.1. Subcutaneous 11.6.2. Intravenous 11.6.3. Oral 11.7. North America Pemphigus Vulgaris Market Value Share Analysis, By End-Users 11.8. North America Pemphigus Vulgaris Market Forecast, By End-Users 11.8.1. Research & Academic Laboratories 11.8.2. Specialty Dermatology Clinics 11.8.3. Hospitals & Clinics 11.8.4. Retailers 11.8.5. Pharmacy 11.8.6. E-Commerce 11.9. North America Pemphigus Vulgaris Market Value Share Analysis, by Country 11.10. North America Pemphigus Vulgaris Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Pemphigus Vulgaris Market Analysis, by Country 11.12. U.S. Pemphigus Vulgaris Market Forecast, By Treatment 11.12.1. Intravenous Immunoglobulin (IVIG) Therapy 11.12.2. Corticosteroids 11.12.3. Immunosuppressant’s 11.12.4. Biological Therapies 11.12.5. Others 11.13. U.S. Pemphigus Vulgaris Market Forecast, By Route of Administration 11.13.1. Subcutaneous 11.13.2. Intravenous 11.13.3. Oral 11.14. U.S. Pemphigus Vulgaris Market Forecast, By End-Users 11.14.1. Research & Academic Laboratories 11.14.2. Specialty Dermatology Clinics 11.14.3. Hospitals & Clinics 11.14.4. Retailers 11.14.5. Pharmacy 11.14.6. E-Commerce 11.15. Canada Pemphigus Vulgaris Market Forecast, By Treatment 11.15.1. Intravenous Immunoglobulin (IVIG) Therapy 11.15.2. Corticosteroids 11.15.3. Immunosuppressant’s 11.15.4. Biological Therapies 11.15.5. Others 11.16. Steel Canada Pemphigus Vulgaris Market Forecast, By Route of Administration 11.16.1. Subcutaneous 11.16.2. Intravenous 11.16.3. Oral 11.17. Canada Pemphigus Vulgaris Market Forecast, By End-Users 11.17.1. Research & Academic Laboratories 11.17.2. Specialty Dermatology Clinics 11.17.3. Hospitals & Clinics 11.17.4. Retailers 11.17.5. Pharmacy 11.17.6. E-Commerce 11.18. North America Pemphigus Vulgaris Market Attractiveness Analysis 11.18.1. By Treatment 11.18.2. By Route of Administration 11.18.3. By End-Users 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Pemphigus Vulgaris Market Analysis 12.1. Key Findings 12.2. Europe Pemphigus Vulgaris Market Overview 12.3. Europe Pemphigus Vulgaris Market Value Share Analysis, By Treatment 12.4. Europe Pemphigus Vulgaris Market Forecast, By Treatment 12.4.1. Intravenous Immunoglobulin (IVIG) Therapy 12.4.2. Corticosteroids 12.4.3. Immunosuppressant’s 12.4.4. Biological Therapies 12.4.5. Others 12.5. Europe Pemphigus Vulgaris Market Value Share Analysis, By Route of Administration 12.6. Europe Pemphigus Vulgaris Market Forecast, By Route of Administration 12.6.1. Subcutaneous 12.6.2. Intravenous 12.6.3. Oral 12.7. Europe Pemphigus Vulgaris Market Value Share Analysis, By End-Users 12.8. Europe Pemphigus Vulgaris Market Forecast, By End-Users 12.8.1. Research & Academic Laboratories 12.8.2. Specialty Dermatology Clinics 12.8.3. Hospitals & Clinics 12.8.4. Retailers 12.8.5. Pharmacy 12.8.6. E-Commerce 12.9. Europe Pemphigus Vulgaris Market Value Share Analysis, by Country 12.10. Europe Pemphigus Vulgaris Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Pemphigus Vulgaris Market Analysis, by Country 12.12. Germany Pemphigus Vulgaris Market Forecast, By Treatment 12.12.1. Intravenous Immunoglobulin (IVIG) Therapy 12.12.2. Corticosteroids 12.12.3. Immunosuppressant’s 12.12.4. Biological Therapies 12.12.5. Others 12.13. Germany Pemphigus Vulgaris Market Forecast, By Route of Administration 12.13.1. Subcutaneous 12.13.2. Intravenous 12.13.3. Oral 12.14. Germany Pemphigus Vulgaris Market Forecast, By End-Users 12.14.1. Research & Academic Laboratories 12.14.2. Specialty Dermatology Clinics 12.14.3. Hospitals & Clinics 12.14.4. Retailers 12.14.5. Pharmacy 12.14.6. E-Commerce 12.15. U.K. Pemphigus Vulgaris Market Forecast, By Treatment 12.15.1. Intravenous Immunoglobulin (IVIG) Therapy 12.15.2. Corticosteroids 12.15.3. Immunosuppressant’s 12.15.4. Biological Therapies 12.15.5. Others 12.16. U.K. Pemphigus Vulgaris Market Forecast, By Route of Administration 12.16.1. Subcutaneous 12.16.2. Intravenous 12.16.3. Oral 12.17. U.K. Pemphigus Vulgaris Market Forecast, By End-Users 12.17.1. Research & Academic Laboratories 12.17.2. Specialty Dermatology Clinics 12.17.3. Hospitals & Clinics 12.17.4. Retailers 12.17.5. Pharmacy 12.17.6. E-Commerce 12.18. France Pemphigus Vulgaris Market Forecast, By Treatment 12.18.1. Intravenous Immunoglobulin (IVIG) Therapy 12.18.2. Corticosteroids 12.18.3. Immunosuppressant’s 12.18.4. Biological Therapies 12.18.5. Others 12.19. France Pemphigus Vulgaris Market Forecast, By Route of Administration 12.19.1. Subcutaneous 12.19.2. Intravenous 12.19.3. Oral 12.20. France Pemphigus Vulgaris Market Forecast, By End-Users 12.20.1. Research & Academic Laboratories 12.20.2. Specialty Dermatology Clinics 12.20.3. Hospitals & Clinics 12.20.4. Retailers 12.20.5. Pharmacy 12.20.6. E-Commerce 12.21. Italy Pemphigus Vulgaris Market Forecast, By Treatment 12.21.1. Intravenous Immunoglobulin (IVIG) Therapy 12.21.2. Corticosteroids 12.21.3. Immunosuppressant’s 12.21.4. Biological Therapies 12.21.5. Others 12.22. Italy Pemphigus Vulgaris Market Forecast, By Route of Administration 12.22.1. Subcutaneous 12.22.2. Intravenous 12.22.3. Oral 12.23. Italy Pemphigus Vulgaris Market Forecast, By End-Users 12.23.1. Research & Academic Laboratories 12.23.2. Specialty Dermatology Clinics 12.23.3. Hospitals & Clinics 12.23.4. Retailers 12.23.5. Pharmacy 12.23.6. E-Commerce 12.24. Spain Pemphigus Vulgaris Market Forecast, By Treatment 12.24.1. Intravenous Immunoglobulin (IVIG) Therapy 12.24.2. Corticosteroids 12.24.3. Immunosuppressant’s 12.24.4. Biological Therapies 12.24.5. Others 12.25. Spain Pemphigus Vulgaris Market Forecast, By Route of Administration 12.25.1. Subcutaneous 12.25.2. Intravenous 12.25.3. Oral 12.26. Spain Pemphigus Vulgaris Market Forecast, By End-Users 12.26.1. Research & Academic Laboratories 12.26.2. Specialty Dermatology Clinics 12.26.3. Hospitals & Clinics 12.26.4. Retailers 12.26.5. Pharmacy 12.26.6. E-Commerce 12.27. Rest of Europe Pemphigus Vulgaris Market Forecast, By Treatment 12.27.1. Intravenous Immunoglobulin (IVIG) Therapy 12.27.2. Corticosteroids 12.27.3. Immunosuppressant’s 12.27.4. Biological Therapies 12.27.5. Others 12.28. Rest of Europe Pemphigus Vulgaris Market Forecast, By Route of Administration 12.28.1. Subcutaneous 12.28.2. Intravenous 12.28.3. Oral 12.29. Rest of Europe Pemphigus Vulgaris Market Forecast, By End-Users 12.29.1. Research & Academic Laboratories 12.29.2. Specialty Dermatology Clinics 12.29.3. Hospitals & Clinics 12.29.4. Retailers 12.29.5. Pharmacy 12.29.6. E-Commerce 12.30. Europe Pemphigus Vulgaris Market Attractiveness Analysis 12.30.1. By Treatment 12.30.2. By Route of Administration 12.30.3. By End-Users 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Pemphigus Vulgaris Market Analysis 13.1. Key Findings 13.2. Asia Pacific Pemphigus Vulgaris Market Overview 13.3. Asia Pacific Pemphigus Vulgaris Market Value Share Analysis, By Treatment 13.4. Asia Pacific Pemphigus Vulgaris Market Forecast, By Treatment 13.4.1. Intravenous Immunoglobulin (IVIG) Therapy 13.4.2. Corticosteroids 13.4.3. Immunosuppressant’s 13.4.4. Biological Therapies 13.4.5. Others 13.5. Asia Pacific Pemphigus Vulgaris Market Value Share Analysis, By Route of Administration 13.6. Asia Pacific Pemphigus Vulgaris Market Forecast, By Route of Administration 13.6.1. Subcutaneous 13.6.2. Intravenous 13.6.3. Oral 13.7. Asia Pacific Pemphigus Vulgaris Market Value Share Analysis, By End-Users 13.8. Asia Pacific Pemphigus Vulgaris Market Forecast, By End-Users 13.8.1. Research & Academic Laboratories 13.8.2. Specialty Dermatology Clinics 13.8.3. Hospitals & Clinics 13.8.4. Retailers 13.8.5. Pharmacy 13.8.6. E-Commerce 13.9. Asia Pacific Pemphigus Vulgaris Market Value Share Analysis, by Country 13.10. Asia Pacific Pemphigus Vulgaris Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Pemphigus Vulgaris Market Analysis, by Country 13.12. China Pemphigus Vulgaris Market Forecast, By Treatment 13.12.1. Intravenous Immunoglobulin (IVIG) Therapy 13.12.2. Corticosteroids 13.12.3. Immunosuppressant’s 13.12.4. Biological Therapies 13.12.5. Others 13.13. China Pemphigus Vulgaris Market Forecast, By Route of Administration 13.13.1. Subcutaneous 13.13.2. Intravenous 13.13.3. Oral 13.14. China Pemphigus Vulgaris Market Forecast, By End-Users 13.14.1. Research & Academic Laboratories 13.14.2. Specialty Dermatology Clinics 13.14.3. Hospitals & Clinics 13.14.4. Retailers 13.14.5. Pharmacy 13.14.6. E-Commerce 13.15. India Pemphigus Vulgaris Market Forecast, By Treatment 13.15.1. Intravenous Immunoglobulin (IVIG) Therapy 13.15.2. Corticosteroids 13.15.3. Immunosuppressant’s 13.15.4. Biological Therapies 13.15.5. Others 13.16. India Pemphigus Vulgaris Market Forecast, By Route of Administration 13.16.1. Subcutaneous 13.16.2. Intravenous 13.16.3. Oral 13.17. India Pemphigus Vulgaris Market Forecast, By End-Users 13.17.1. Research & Academic Laboratories 13.17.2. Specialty Dermatology Clinics 13.17.3. Hospitals & Clinics 13.17.4. Retailers 13.17.5. Pharmacy 13.17.6. E-Commerce 13.18. Japan Pemphigus Vulgaris Market Forecast, By Treatment 13.18.1. Intravenous Immunoglobulin (IVIG) Therapy 13.18.2. Corticosteroids 13.18.3. Immunosuppressant’s 13.18.4. Biological Therapies 13.18.5. Others 13.19. Japan Pemphigus Vulgaris Market Forecast, By Route of Administration 13.19.1. Subcutaneous 13.19.2. Intravenous 13.19.3. Oral 13.20. Japan Pemphigus Vulgaris Market Forecast, By End-Users 13.20.1. Research & Academic Laboratories 13.20.2. Specialty Dermatology Clinics 13.20.3. Hospitals & Clinics 13.20.4. Retailers 13.20.5. Pharmacy 13.20.6. E-Commerce 13.21. ASEAN Pemphigus Vulgaris Market Forecast, By Treatment 13.21.1. Intravenous Immunoglobulin (IVIG) Therapy 13.21.2. Corticosteroids 13.21.3. Immunosuppressant’s 13.21.4. Biological Therapies 13.21.5. Others 13.22. ASEAN Pemphigus Vulgaris Market Forecast, By Route of Administration 13.22.1. Subcutaneous 13.22.2. Intravenous 13.22.3. Oral 13.23. ASEAN Pemphigus Vulgaris Market Forecast, By End-Users 13.23.1. Research & Academic Laboratories 13.23.2. Specialty Dermatology Clinics 13.23.3. Hospitals & Clinics 13.23.4. Retailers 13.23.5. Pharmacy 13.23.6. E-Commerce 13.24. Rest of Asia Pacific Pemphigus Vulgaris Market Forecast, By Treatment 13.24.1. Intravenous Immunoglobulin (IVIG) Therapy 13.24.2. Corticosteroids 13.24.3. Immunosuppressant’s 13.24.4. Biological Therapies 13.24.5. Others 13.25. Rest of Asia Pacific Pemphigus Vulgaris Market Forecast, By Route of Administration 13.25.1. Subcutaneous 13.25.2. Intravenous 13.25.3. Oral 13.26. Rest of Asia Pacific Pemphigus Vulgaris Market Forecast, By End-Users 13.26.1. Research & Academic Laboratories 13.26.2. Specialty Dermatology Clinics 13.26.3. Hospitals & Clinics 13.26.4. Retailers 13.26.5. Pharmacy 13.26.6. E-Commerce 13.27. Asia Pacific Pemphigus Vulgaris Market Attractiveness Analysis 13.27.1. By Treatment 13.27.2. By Route of Administration 13.27.3. By End-Users 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Pemphigus Vulgaris Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Pemphigus Vulgaris Market Overview 14.3. Middle East & Africa Pemphigus Vulgaris Market Value Share Analysis, By Treatment 14.4. Middle East & Africa Pemphigus Vulgaris Market Forecast, By Treatment 14.4.1. Intravenous Immunoglobulin (IVIG) Therapy 14.4.2. Corticosteroids 14.4.3. Immunosuppressant’s 14.4.4. Biological Therapies 14.4.5. Others 14.5. Middle East & Africa Pemphigus Vulgaris Market Value Share Analysis, By Route of Administration 14.6. Middle East & Africa Pemphigus Vulgaris Market Forecast, By Route of Administration 14.6.1. Subcutaneous 14.6.2. Intravenous 14.6.3. Oral 14.7. Middle East & Africa Pemphigus Vulgaris Market Value Share Analysis, By End-Users 14.8. Middle East & Africa Pemphigus Vulgaris Market Forecast, By End-Users 14.8.1. Research & Academic Laboratories 14.8.2. Specialty Dermatology Clinics 14.8.3. Hospitals & Clinics 14.8.4. Retailers 14.8.5. Pharmacy 14.8.6. E-Commerce 14.9. Middle East & Africa Pemphigus Vulgaris Market Value Share Analysis, by Country 14.10. Middle East & Africa Pemphigus Vulgaris Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Pemphigus Vulgaris Market Analysis, by Country 14.12. GCC Pemphigus Vulgaris Market Forecast, By Treatment 14.12.1. Intravenous Immunoglobulin (IVIG) Therapy 14.12.2. Corticosteroids 14.12.3. Immunosuppressant’s 14.12.4. Biological Therapies 14.12.5. Others 14.13. GCC Pemphigus Vulgaris Market Forecast, By Route of Administration 14.13.1. Subcutaneous 14.13.2. Intravenous 14.13.3. Oral 14.14. GCC Pemphigus Vulgaris Market Forecast, By End-Users 14.14.1. Research & Academic Laboratories 14.14.2. Specialty Dermatology Clinics 14.14.3. Hospitals & Clinics 14.14.4. Retailers 14.14.5. Pharmacy 14.14.6. E-Commerce 14.15. South Africa Pemphigus Vulgaris Market Forecast, By Treatment 14.15.1. Intravenous Immunoglobulin (IVIG) Therapy 14.15.2. Corticosteroids 14.15.3. Immunosuppressant’s 14.15.4. Biological Therapies 14.15.5. Others 14.16. South Africa Pemphigus Vulgaris Market Forecast, By Route of Administration 14.16.1. Subcutaneous 14.16.2. Intravenous 14.16.3. Oral 14.17. South Africa Pemphigus Vulgaris Market Forecast, By End-Users 14.17.1. Research & Academic Laboratories 14.17.2. Specialty Dermatology Clinics 14.17.3. Hospitals & Clinics 14.17.4. Retailers 14.17.5. Pharmacy 14.17.6. E-Commerce 14.18. Rest of Middle East & Africa Pemphigus Vulgaris Market Forecast, By Treatment 14.18.1. Intravenous Immunoglobulin (IVIG) Therapy 14.18.2. Corticosteroids 14.18.3. Immunosuppressant’s 14.18.4. Biological Therapies 14.18.5. Others 14.19. Rest of Middle East & Africa Pemphigus Vulgaris Market Forecast, By Route of Administration 14.19.1. Subcutaneous 14.19.2. Intravenous 14.19.3. Oral 14.20. Rest of Middle East & Africa Pemphigus Vulgaris Market Forecast, By End-Users 14.20.1. Research & Academic Laboratories 14.20.2. Specialty Dermatology Clinics 14.20.3. Hospitals & Clinics 14.20.4. Retailers 14.20.5. Pharmacy 14.20.6. E-Commerce 14.21. Middle East & Africa Pemphigus Vulgaris Market Attractiveness Analysis 14.21.1. By Treatment 14.21.2. By Route of Administration 14.21.3. By End-Users 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Pemphigus Vulgaris Market Analysis 15.1. Key Findings 15.2. South America Pemphigus Vulgaris Market Overview 15.3. South America Pemphigus Vulgaris Market Value Share Analysis, By Treatment 15.4. South America Pemphigus Vulgaris Market Forecast, By Treatment 15.4.1. Intravenous Immunoglobulin (IVIG) Therapy 15.4.2. Corticosteroids 15.4.3. Immunosuppressant’s 15.4.4. Biological Therapies 15.4.5. Others 15.5. South America Pemphigus Vulgaris Market Value Share Analysis, By Route of Administration 15.6. South America Pemphigus Vulgaris Market Forecast, By Route of Administration 15.6.1. Subcutaneous 15.6.2. Intravenous 15.6.3. Oral 15.7. South America Pemphigus Vulgaris Market Value Share Analysis, By End-Users 15.8. South America Pemphigus Vulgaris Market Forecast, By End-Users 15.8.1. Research & Academic Laboratories 15.8.2. Specialty Dermatology Clinics 15.8.3. Hospitals & Clinics 15.8.4. Retailers 15.8.5. Pharmacy 15.8.6. E-Commerce 15.9. South America Pemphigus Vulgaris Market Value Share Analysis, by Country 15.10. South America Pemphigus Vulgaris Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Pemphigus Vulgaris Market Analysis, by Country 15.12. Brazil Pemphigus Vulgaris Market Forecast, By Treatment 15.12.1. Intravenous Immunoglobulin (IVIG) Therapy 15.12.2. Corticosteroids 15.12.3. Immunosuppressant’s 15.12.4. Biological Therapies 15.12.5. Others 15.13. Brazil Pemphigus Vulgaris Market Forecast, By Route of Administration 15.13.1. Subcutaneous 15.13.2. Intravenous 15.13.3. Oral 15.14. Brazil Pemphigus Vulgaris Market Forecast, By End-Users 15.14.1. Research & Academic Laboratories 15.14.2. Specialty Dermatology Clinics 15.14.3. Hospitals & Clinics 15.14.4. Retailers 15.14.5. Pharmacy 15.14.6. E-Commerce 15.15. Mexico Pemphigus Vulgaris Market Forecast, By Treatment 15.15.1. Intravenous Immunoglobulin (IVIG) Therapy 15.15.2. Corticosteroids 15.15.3. Immunosuppressant’s 15.15.4. Biological Therapies 15.15.5. Others 15.16. Mexico Pemphigus Vulgaris Market Forecast, By Route of Administration 15.16.1. Subcutaneous 15.16.2. Intravenous 15.16.3. Oral 15.17. Mexico Pemphigus Vulgaris Market Forecast, By End-Users 15.17.1. Research & Academic Laboratories 15.17.2. Specialty Dermatology Clinics 15.17.3. Hospitals & Clinics 15.17.4. Retailers 15.17.5. Pharmacy 15.17.6. E-Commerce 15.18. Rest of South America Pemphigus Vulgaris Market Forecast, By Treatment 15.18.1. Intravenous Immunoglobulin (IVIG) Therapy 15.18.2. Corticosteroids 15.18.3. Immunosuppressant’s 15.18.4. Biological Therapies 15.18.5. Others 15.19. Rest of South America Pemphigus Vulgaris Market Forecast, By Route of Administration 15.19.1. Subcutaneous 15.19.2. Intravenous 15.19.3. Oral 15.20. Rest of South America Pemphigus Vulgaris Market Forecast, By End-Users 15.20.1. Research & Academic Laboratories 15.20.2. Specialty Dermatology Clinics 15.20.3. Hospitals & Clinics 15.20.4. Retailers 15.20.5. Pharmacy 15.20.6. E-Commerce 15.21. South America Pemphigus Vulgaris Market Attractiveness Analysis 15.21.1. By Treatment 15.21.2. By Route of Administration 15.21.3. By End-Users 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications, and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Teva Pharmaceutical Industries 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. Novartis Pharmaceuticals, 16.3.3. Hoffmann-La Roche, 16.3.4. Principia Biopharma, Inc, 16.3.5. Argenx 16.3.6. Pfizer Inc., 16.3.7. Teligent Inc, 16.3.8. GlaxoSmithKline LLC, 16.3.9. Almirall 16.3.10. Argenx SE 16.3.11. Biogen Inc 16.3.12. Syntimmune 16.3.13. Sanofi 16.3.14. Janssen Global Services 16.3.15. Genentech Inc. 16.3.16. Celltrion Inc. 16.3.17. Amgen Inc. 16.3.18. Samsung Bioepis. 16.3.19. Fresenius Kabi USA. 16.3.20. Hikma Pharmaceutical PLC. 17. Primary Key Insights

About This Report

Report ID 65970
Category Healthcare
Published Date July 2020
Updated Date June 2021
Contact Us